Kavitha Iyer-Rodrigues, 

In 2014, Theramyt developed a gene knockout platform for producing the next generation of antibodies. “We now have a differentiated set of antibodies,” Rodrigues says. This new generation of antibodies offers higher efficacy with lower dosage and toxicity. Theramyt also has two biosimilars, in diabetes and oncology, in advanced stages. Last year, it clocked six IP prefilings, no mean feat for a not-yetthree-year-old venture. Next year, Iyer-Rodgrigues intends to take Theramyt global for strategic partnerships.